Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8285973 | 0.81 | PTGS2 (0.48) | PTGS2F10TYK2JAK2JAK1 | |
| SCHEMBL23768205 | 0.80 | TYK2 (0.46) | PTGS2F10TYK2JAK2JAK1 | |
| SCHEMBL17688868 | 0.80 | DGAT1 (0.41) | MTOR | |
| SCHEMBL2343226 | 0.80 | F10 (0.49) | PTGS2F10TYK2JAK2JAK1 | |
| SCHEMBL29462406 | 0.80 | F10 (0.49) | PTGS2F10TYK2JAK2JAK1 | |
| SCHEMBL17207184 | 0.78 | AKR1C3 (0.51) | — | |
| SCHEMBL3297140 | 0.78 | PTGS2 (0.48) | PTGS2F10TYK2JAK2JAK1 | |
| SCHEMBL28362833 | 0.78 | F10 (0.53) | PTGS2F10 | |
| SCHEMBL30253118 | 0.78 | PTGS2 (0.48) | PTGS2F10TYK2JAK2JAK1 | |
| SCHEMBL20038363 | 0.78 | PTGS2 (0.47) | PTGS2F10TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PTGS2 3212/4885F10 3694/4885TYK2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.